Spravato, TMS, ECT, antidepressant changes, and psilocybin compared on FDA status, cost, and speed for people weighing options beyond ketamine therapy.
The closest ketamine alternatives for depression are Spravato (esketamine), transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), standard oral antidepressant adjustments, and psilocybin in clinical trials or state-regulated facilities. At Mind Medicine Law, we track federal scheduling, clinical trials, and emerging mental health regulations so you can see what exists legally today.
People look for alternatives to ketamine therapy for practical reasons. Intravenous (IV) ketamine remains an off-label depression treatment, which means insurance plans rarely pay for the sessions. Between out-of-pocket clinic bills, dissociative side effects, and cases where ketamine produces no symptom relief, you have several medically recognized paths to explore with a prescriber.
High out-of-pocket costs and lack of insurance coverage drive most searches for ketamine alternatives. Ketamine is an NMDA (N-methyl-D-aspartate) glutamate receptor antagonist and a Schedule III controlled substance under federal law. The Food and Drug Administration (FDA) approves ketamine solely as an anesthetic, so all IV and intramuscular (IM) ketamine protocols for depression operate off-label.
A typical IV ketamine infusion costs between $400 and $800 per session, and you generally pay the full amount yourself. At-home telehealth lozenge programs offer a lower financial barrier at roughly $150 to $400 per month, yet insurance still rarely covers the medication or clinical oversight. You can review full treatment pricing in our guide on how much ketamine therapy costs.
Clinical limits may also prompt you to seek different treatments. A single sub-anesthetic dose of ketamine can reduce depressive symptoms within hours to days, but the effect typically fades within days without ongoing repeat sessions. You may also encounter acute side effects like dissociation, temporary blood pressure spikes, nausea, and dizziness, while heavy, frequent long-term use carries bladder problems and abuse risk.
Spravato is the closest direct alternative to ketamine because it consists of esketamine, the S-enantiomer half of the ketamine molecule. Delivered as a nasal spray at 56 mg or 84 mg doses, Spravato is self-administered inside a certified healthcare setting under a federal Risk Evaluation and Mitigation Strategy (REMS) program. You remain under clinical observation for about two hours after dosing before someone drives you home.
The primary difference between the two treatments centers on regulatory approval and insurance reimbursement rather than physical side effects. The FDA approved Spravato for treatment-resistant depression in 2019 alongside an oral antidepressant, and in January 2025 expanded approval to allow Spravato as a standalone therapy. Commercial health plans and Medicare frequently cover Spravato if you are eligible.
List prices run between $600 and $900 per session before insurance, plus separate clinic observation fees. Treatment usually begins with two sessions weekly during the first month before tapering to maintenance frequencies. Because Spravato shares the same molecular pharmacology as ketamine, it carries identical risks of dissociation and elevated blood pressure, making it an alternative for coverage rather than side-effect avoidance.
Transcranial magnetic stimulation provides a non-pharmacological alternative that avoids the dissociative effects of ketamine entirely. TMS places an electromagnetic coil against the scalp to deliver focused magnetic pulses to mood-regulating regions of the brain. You remain fully awake throughout the procedure, receive no sedatives or anesthetics, and can drive yourself home immediately afterward.
The FDA cleared TMS for major depressive disorder in 2008. A standard treatment course involves roughly 36 sessions scheduled five days a week over six weeks, with individual visits lasting 20 to 40 minutes. Most people notice change after three to six weeks of daily sessions.
An accelerated approach called the SAINT protocol secured FDA clearance in 2022, using individualized brain imaging to deliver targeted stimulation across a shorter timeframe that can show benefits within days. Most commercial insurers and Medicare cover standard TMS after you fail two or more antidepressants. Without insurance, a full course can reach several thousand dollars, with adverse effects limited primarily to scalp discomfort, mild headaches, facial muscle twitching, and a very low risk of seizures.
Electroconvulsive therapy has the longest and deepest evidence base of any depression treatment discussed here and is generally considered the most effective option for the most severe depression, including depression with psychotic features. ECT induces a brief, medically controlled seizure using precise electrical currents under general anesthesia with a muscle relaxant. Treatments take place within hospitals or specialized outpatient surgical centers, typically spanning 6 to 12 sessions across two to four weeks. Maintenance sessions may follow.
The primary drawback of ECT is its cognitive and memory profile. You may experience short-term memory loss around the time of treatment, and less commonly longer gaps in memory for events before treatment. The severity of memory side effects varies by person and technique.
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) hold FDA approval for major depressive disorder, costing roughly $10 to $75 per month out of pocket without insurance. However, oral medications work on a different timeline than ketamine, usually requiring four to six weeks to establish a therapeutic response.
Remission outcomes across multiple oral medication trials remain an area of scientific debate. In the STAR*D trial published by Trivedi and colleagues in the American Journal of Psychiatry in 2006, between 28% and 33% of nearly 3,000 patients achieved remission on their initial medication. The original trial authors calculated a theoretical cumulative remission rate of roughly 67% across four successive medication steps.
A 2024 reanalysis published in World Psychiatry re-evaluated STAR*D data using the trial's protocol-specified rating scale and found an actual cumulative remission rate of 35.0% after four treatment steps. While oral medications cost far less than ketamine infusions, their slower onset and contested multi-step remission rates explain why you might explore interventional alternatives when two or more oral trials fail.
Psilocybin is an investigational alternative that operates within a strictly limited legal framework. Under federal law, psilocybin remains a Schedule I controlled substance with no FDA approval for any medical condition as of 2026. However, the FDA granted psilocybin two Breakthrough Therapy designations: COMPASS Pathways in 2018 for treatment-resistant depression, and the Usona Institute in 2019 for major depressive disorder.
In June 2025, COMPASS Pathways announced primary endpoint results from its Phase 3 COMP005 trial (NCT05624268) involving 258 adults with treatment-resistant depression. A single 25 mg dose of synthesized psilocybin achieved a statistically significant mean difference of -3.6 points on the Montgomery-Asberg Depression Rating Scale (MADRS) at week six compared to placebo (p<0.001).
Supervised legal access remains limited to regulated state programs or authorized clinical trials. Oregon allows adult non-medical administration under Measure 109, where center fees range from $1,800 to $3,000 per session without insurance reimbursement. Colorado began licensing healing centers in 2025 under Proposition 122. SSRIs and SNRIs can blunt psilocybin's effects, so trial protocols and licensed facilitators commonly require a supervised taper first with your prescriber, since stopping abruptly can cause discontinuation syndrome.
SSRIs and SNRIs cost the least, at about $10 to $75 a month out of pocket without insurance.
| Option | FDA status | Typical cost | Time to effect | Main drawback |
|---|---|---|---|---|
| Spravato (esketamine) | FDA-approved for treatment-resistant depression (approved as standalone treatment in January 2025) | Roughly $600 to $900 per session before insurance plus a clinic monitoring fee; often covered by commercial insurance and Medicare | Not covered here (sessions run twice weekly for the first month) | Requires administration in a certified healthcare setting under REMS with two hours of monitoring, and can cause dissociation and elevated blood pressure |
| TMS | FDA-cleared for major depression since 2008; SAINT protocol cleared in 2022 | Several thousand dollars without coverage; covered by most insurance plans and Medicare after two or more antidepressant failures | Three to six weeks for standard courses; within days for some patients under the SAINT protocol | Requires a time commitment of about 36 sessions over six weeks; side effects include scalp discomfort and headache |
| ECT | Not covered here | Not covered here | Not covered here (a typical course is 6 to 12 sessions over 2 to 4 weeks) | Memory-related side effects, including short-term memory loss around treatment, and requires general anesthesia |
| SSRIs and SNRIs | FDA-approved for major depressive disorder | About $10 to $75 a month out of pocket without insurance | Four to six weeks for full effect | Remission rate of 28% to 33% on the first medication tried, and risk of discontinuation syndrome if stopped abruptly |
| Psilocybin | No FDA approval; Schedule I controlled substance holding two FDA Breakthrough Therapy designations | About $1,800 to $3,000 per session in Oregon licensed centers; not covered by insurance; not covered here for Colorado or clinical trials | Trial primary endpoint measured at week 6; otherwise not covered here | Federal Schedule I status, narrow legal access limited to Oregon, Colorado, or clinical trials, and therapeutic effects are blunted by SSRIs or SNRIs |
Some psychiatric clinics combine different modalities or sequence them sequentially when a single treatment yields an incomplete response. Certain centers combine TMS and ketamine, or administer one after the other fails to produce full remission. Because TMS delivers focal electromagnetic stimulation to cortical mood circuits while ketamine acts chemically on NMDA receptors, the two therapies operate through separate biological pathways.
Clinical evidence evaluating concurrent TMS and ketamine protocols remains early and unestablished. Ketamine does not cancel out the biological action of standard antidepressants, and most clinics keep you on your existing oral antidepressant during an infusion series. Conversely, SSRIs and SNRIs can blunt psilocybin's effects, so trial protocols and licensed facilitators commonly require a supervised taper first.
These alternative therapies do not serve you if you are in crisis or experiencing active suicidal thoughts. Anyone in acute distress must call or text 988 or go to an emergency room for urgent stabilization rather than researching outpatient alternatives.
This guide also does not apply if you are currently stable on ketamine or an antidepressant and are considering stopping on your own. Furthermore, if you are expecting psilocybin to be a ready substitute, you should know that access remains narrow.
Our evaluation of these treatment pathways would change if the FDA grants formal market approval to psilocybin for major depressive disorder or treatment-resistant depression.
A second factor that would reshape this comparison is broad insurance coverage for off-label IV ketamine. If major commercial insurers and Medicare begin covering off-label IV ketamine infusions, the primary practical advantage of Spravato over IV clinic sessions would diminish. Finally, head-to-head clinical trials directly comparing TMS, Spravato, and psilocybin would provide clearer comparative efficacy data than currently exists.
The best alternative depends on whether you need insurance coverage, rapid relief, or a medication-free approach. Spravato provides a similar molecular mechanism covered by most insurance plans, while TMS offers a non-drug option cleared by the FDA for major depression. Discuss your treatment history with a prescriber to evaluate which option fits your clinical profile.
Spravato is not clinically proven to be better than IV ketamine, but it holds key regulatory advantages. Spravato contains esketamine and is FDA-approved for treatment-resistant depression, which allows commercial insurance and Medicare to cover it. Both medications carry similar side effects, including dissociation, nausea, and temporary blood pressure spikes during dosing.
Direct comparative trials between TMS and ketamine remain limited. TMS is FDA-cleared and produces steady improvement across three to six weeks of daily outpatient sessions, whereas ketamine acts faster, often within hours. TMS avoids drug-related side effects entirely, while ketamine carries risks of dissociation.
If ketamine produces no symptom relief, standard clinical alternatives include TMS, ECT, or adjusting oral antidepressants. ECT has the longest and deepest evidence base of any depression treatment discussed here and is generally considered the most effective option for the most severe depression, including depression with psychotic features. You can also explore investigational psilocybin clinical trials or licensed state centers in Oregon and Colorado.
Standard oral SSRIs and SNRIs typically cost $10 to $75 per month without insurance. For treatment-resistant depression, Spravato is often covered for eligible patients and TMS after two failed antidepressants, substantially reducing out-of-pocket costs compared to $400 to $800 per IV ketamine session.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.